Psychiatry has suffered tremendously by the limited translational pipeline. Nobel laureate Julius Axelrod's discovery in 1961 of monoamine reuptake by pre-synaptic neurons still forms the basis of contemporary antidepressant treatment. There is a grievous gap between the explosion of knowledge in neuroscience and conceptually novel treatments for our patients. Translational Psychiatry bridges this gap by fostering and highlighting the pathway from discovery to clinical applications, healthcare and global health. We view translation broadly as the full spectrum of work that marks the pathway from discovery to global health, inclusive. The steps of translation that are within the scope of Translational Psychiatry include (i) fundamental discovery, (ii) bench to bedside, (iii) bedside to clinical applications (clinical trials), (iv) translation to policy and health care guidelines, (v) assessment of health policy and usage, and (vi) global health. All areas of medical research, including — but not restricted to — molecular biology, genetics, pharmacology, imaging and epidemiology are welcome as they contribute to enhance the field of translational psychiatry.

转化渠道有限，给精神病学带来了巨大的损失。诺贝尔奖获得者朱利叶斯·阿克塞尔罗德于 1961 年发现突触前神经元对单胺的再摄取，这仍然是当代抗抑郁治疗的基础。神经科学知识的爆炸式增长与患者概念上新颖的治疗方法之间存在着巨大的差距。转化精神病学通过促进和强调从发现到临床应用、医疗保健和全球健康的途径来弥合这一差距。我们将转化视为从发现到全球健康之路的全方位工作。转化精神病学范围内的转化步骤包括 (i) 基础发现、(ii) 从实验室到临床、(iii) 从临床到临床应用（临床试验）、(iv) 转化为政策和医疗保健指南、(v) 评估卫生政策和使用情况，以及 (vi) 全球健康。欢迎所有医学研究领域，包括但不限于分子生物学、遗传学、药理学、成像和流行病学，因为它们有助于促进转化精神病学领域的发展。

该刊已被国际权威数据库SCIE收录，是国际顶级期刊。该刊致力于发表经过严格同行评审的高质量原创文章，反映PSYCHIATRY领域的新进展、新技术、新成果，促进该领域科研交流和科研成果转化。该刊2023年影响因子为5.8，平均审稿速度为 23 Weeks ，近四年来没有被列入预警名单。如果您需要投稿发表服务及指导，可以联系我们的客服老师，我们专业专注服务期刊投稿协助10年，为您提供期刊投稿个性化定制服务，并且我们确保严格保密您的个人信息及稿件内容。